This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Thomas Stegmann

Thomas tstegmann Stegmann, Professor, M.D., PhD

MHH, Germany; CardioVascular BioTherapeutics, Inc. (Venturis Therapeutics, Inc.); Phage Pharmaceuticals, Inc., San Diego, USA.
Spiegel-Str. 10
Petersberg  D-36100
+49 661 604772
+49 171 7475458 (alternative)
You need to be logged in to see this email (login)
Surgeon - Cardiothoracic


Studies of Human Medicine: Final Examination - 1974
Doctor Thesis (Dissertation): summa cum laude - 1974
Price of Faculty (University of Heidelberg) - 1974
Hannover Medical School (MHH) 1976 - present; Prof.Borst, Prof.Pichlmayr, Prof.Tscherne
Licenses: General Surgery - 1982, Cardiothoracic & Vascular Surgery - 1983
Rudolf-Nissen-Memorial-Award - 1982; Appointment Professor of Surgery - 1989
Head of the Dept. of Thoracic & Cardiovascular Surgery, Fulda Medical Center (1984-2006)
Faculty Member MHH (since 1982); Founder, CardioVascular BioTherapeutics, Inc. (1998)
Member - New York Academy of Sciences (since 2007); Member - Ukrainian Academy of Med. Sciences
Founder, CMO, Board-Member, CardioVascular Therapeutics, Inc., Las Vegas, NV, USA
CEO, Phage Pharmaceuticals, Inc., USA

Other Interests



Angiogenic Therapy of Coronary Heart Disease
Angiogenesis, Myogenesis
Aortic Dissection
Heart & Lung Transplantation
Coronary Bypass Surgery
Angiogenic Growth Factors
Abdominal Aortic Aneurysm - Surgical Treatment
Surgery of the Aorta

Additional Educational Information

Hannover Medical School (MHH), Germany

Practice Areas

  • Cardiac
  • Thoracic
  • Vascular
  • Minimally Invasive
  • Coronary disease
  • Electrophysiology/arrhythmia
  • Extracorporeal circulation
  • Heart failure
  • Pericardium
  • Thoracic
  • Diaphragm
  • Mediastinum
  • Pleura
  • Congenital
  • Aorta
  • Critical Care
  • Basic science